ArticleInternational journal of colorectal disease2024

Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis.

Yen-Cheng Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.